Neulasta® - Product Information

Neulasta® (pefgilgrastim). Start with support

Product

Information

Download the PDF version of Prescribing Information (PDF, 54 Kb)

Download the PDF version of Patient Product Information (PDF, 197 Kb)

You need to have Adobe^® Acrobat^® installed to view PDF files. If you do not have Acrobat^® Reader^®, you can download it for free from Adobe^® website.

Adobe^® Reader^® is a registered trademark of Adobe Systems, Inc.


	Neulasta^® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. Important Product Safety Information Neulasta^® Prescribing Information \| NEUPOGEN^® (Filgrastim) Prescribing Information \| Medical Information Connection™ \| Site Map \| Amgen.com 2009 Amgen. All rights reserved. This site for use in U.S. only.